Johnson & Johnson Seeks Innovation Leader in Leiden
Leiden, Friday, 7 March 2025.
Johnson & Johnson is hiring for a key role in Leiden, reflecting its commitment to advancing biotech manufacturing technology.
Strategic Focus on Biopharmaceutical Innovation
The recruitment drive at Johnson & Johnson’s Leiden facility underscores the company’s commitment to advancing biopharmaceutical manufacturing technology. The MSAT Innovation LM S&D Manager role will be instrumental in leading the implementation of new technologies and sustainable manufacturing concepts [1]. This position aligns with Johnson & Johnson’s broader mission to innovate across the healthcare spectrum, particularly in developing treatments for complex diseases [2].
Advanced Technical Leadership Requirements
The position demands high-level expertise, requiring a Master’s degree and a minimum of five years of hands-on experience in biopharmaceutical manufacturing [1]. The role involves critical responsibilities including technical integration of new processes, co-leading global deployment of MVA (Multivariate Analysis) platforms, and spearheading manufacturing output enhancement projects [2]. The successful candidate will need to demonstrate proficiency in PAT (Process Analytical Technology) tools within GMP manufacturing environments [1][2].
Integration with Global Healthcare Innovation
This strategic appointment comes at a significant time for Johnson & Johnson’s innovative medicine division. The company’s recent developments include breakthrough progress in multiple myeloma treatment, as evidenced by the positive CHMP opinion received for DARZALEX® in February 2025 [5]. The role will contribute to Johnson & Johnson’s broader mission of developing smarter, less invasive treatments and personalized healthcare solutions [4].
Collaborative Research and Development Focus
Based at the Leiden facility, the position will involve collaboration with R&D, Quality, and Regulatory teams to ensure manufacturing processes meet current and future demands [1]. The role requires travel commitments of 10-25%, depending on project requirements [2], facilitating partnerships with external manufacturing partners and ensuring consistent implementation of innovative technologies across facilities.